Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment
- 134 Downloads
The objective of this study was to assess lithium safety and tolerability and to explore its impact on cognition, function, and neuroimaging biomarkers in human immunodeficiency virus (HIV)-infected subjects with cognitive impairment. Fifteen cognitively impaired HIV-infected subjects were enrolled in this 10-week open-label study of lithium 300 mg twice daily. Neuroimaging was performed at baseline and following 10 weeks of treatment and included magnetic resonance spectroscopy (MRS), diffusion tensor imaging (DTI), and functional MRI (fMRI). Thirteen of the 14 subjects (93%) that complied with the study visits were able to complete the study on lithium and 11 out of 13 (79%) completed the study at the originally assigned dose of 300 mg twice daily. There were no significant changes in CD4+ lymphocyte cell count and plasma HIV RNA. Cognitive performance and depressive mood did not improve significantly after the 10-week lithium treatment; however, neuroimaging revealed a decrease in the glutamate+glutamine (Glx) peak in the frontal gray matter, increased fractional anisotropy, and decreased mean diffusivity in several brain areas, and changes in brain activation patterns, suggestive of improvement. These results suggest that lithium can be used safely in HIV-infected individuals with cognitive impairment. Furthermore, the neuroimaging results suggest that lithium may improve HIV-associated central nervous system (CNS) injury; thus, further investigations of lithium as an adjunctive treatment for HIV-associated cognitive impairment are warranted.
KeywordsHIV lithium cognitive impairment neuroimaging fMRI
Unable to display preview. Download preview PDF.
- Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007). Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69: 1789–1799.CrossRefPubMedGoogle Scholar
- Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders (1996). Clinical confirmation of the American Academy of Neurology algortihm for HIV-1-associated cognitive motor disorder. Neurology, 47: 1247–1253.Google Scholar
- Monkul ES, Matsuo K, Nicoletti MA, Dierschke N, Hatch JP, Dalwani M, Brambilla P, Caetano S, Sassi RB, Mallinger AG, Soares JC (2007). Prefrontal gray matter increases in healthy individuals after lithium treatment: a voxel-based morphometry study. Neurosci Lett 429: 7–11.CrossRefPubMedGoogle Scholar
- Mori S, Oishi K, Jiang H, Jiang L, Li X, Akhter K, Hua K, Faria AV, Mahmood A, Woods R, Toga AW, Pike GB, Neto PR, Evans A, Zhang J, Huang H, Miller MI, van ZP, Mazziotta J (2008). Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage 40: 570–582.CrossRefPubMedGoogle Scholar
- Sacktor N (2006). Magnetic resonance spectroscopy abnormalities using a 3.0 tesla field strength in individuals with HIV dementia. Ann Neurol 60 Suppl 3: S24-S24.Google Scholar
- Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, Jarvik JG, Miller EN, Singer EJ, Ellis RJ, Kolson DL, Simpson D, Nath A, Berger J, Shriver SL, Millar LL, Colquhoun D, Lenkinski R, Gonzalez RG, Lipton SA (2007a). Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 21: 1877–1886.CrossRefPubMedGoogle Scholar
- Schifitto G, Yiannoutsos CT, Ernst T, Navia B, Sacktor N, Nath A, Clifford DB (2007b). Impact of selegiline transdermal system on measures of brain metabolism and markers of oxidative stress in HIV infected individuals with cognitive impairment. J NeuroVirol 13: 122–123.Google Scholar
- Yildiz-Yesiloglu A, Ankerst DP (2006). Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 30: 969–995.CrossRefPubMedGoogle Scholar